Sirolimus

• 

  Subject Areas on Research

  • "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. 
  • "Sirolimus or paclitaxel drug eluting stent in left main disease: the winner is... ". 
  • 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. 
  • 4D MRI of polycystic kidneys from rapamycin-treated Glis3-deficient mice. 
  • A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN. 
  • A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation. 
  • A Tissue Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome Using Human iPSC-derived Smooth Muscle Cells. 
  • A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. 
  • A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 
  • A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. 
  • A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. 
  • A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. 
  • A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. 
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. 
  • A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. 
  • A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. 
  • A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. 
  • AMPK and substrate availability regulate creatine transport in cultured cardiomyocytes. 
  • Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 
  • Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. 
  • Akt/protein kinase B promotes organ growth in transgenic mice. 
  • Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. 
  • An in vivo platform for translational drug development in pancreatic cancer. 
  • Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. 
  • Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis. 
  • Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. 
  • Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. 
  • Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. 
  • Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. 
  • Autophagy modulates articular cartilage vesicle formation in primary articular chondrocytes. 
  • Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. 
  • BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). 
  • Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. 
  • Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. 
  • Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. 
  • Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates. 
  • Bevacizumab and everolimus in renal cancer: a rational way forward. 
  • Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. 
  • Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. 
  • Broad antifungal resistance mediated by RNAi-dependent epimutation in the basal human fungal pathogen Mucor circinelloides. 
  • CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. 
  • CD154 blockade, sirolimus, and donor-specific transfusion prevents renal allograft rejection in cynomolgus monkeys despite homeostatic T-cell activation. 
  • CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. 
  • CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. 
  • CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. 
  • CD8+ T cells: mechanistic target of rapamycin and eukaryotic initiation factor 2 in elite HIV-1 control. 
  • Calcineurin is required for virulence of Cryptococcus neoformans. 
  • Calorie restriction alleviates the age-related decrease in neural progenitor cell division in the aging brain. 
  • Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. 
  • Caution in interpreting the findings from small observational studies. 
  • Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. 
  • Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. 
  • Challenges and Emerging Opportunities for Targeting mTOR in Cancer. 
  • Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. 
  • Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. 
  • Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. 
  • Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. 
  • Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study. 
  • Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: one year results from the XIENCE V® USA condition of approval post-market study. 
  • Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents. 
  • Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. 
  • Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. 
  • Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. 
  • Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. 
  • Coming of age: molecular drivers of aging and therapeutic opportunities. 
  • Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. 
  • Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. 
  • Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. 
  • Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. 
  • Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. 
  • Correction of glycogen storage disease type III with rapamycin in a canine model. 
  • Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. 
  • Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. 
  • Cytocidal amino acid starvation of Saccharomyces cerevisiae and Candida albicans acetolactate synthase (ilv2{Delta}) mutants is influenced by the carbon source and rapamycin. 
  • Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. 
  • DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study. 
  • Decellularized tissue-engineered blood vessel as an arterial conduit. 
  • Differential effects of calorie restriction and rapamycin on age-related molecular and functional changes in skeletal muscle. 
  • Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. 
  • Discovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D Microarrays. 
  • Disruption of the gene encoding the mitogen-regulated translational modulator PHAS-I in mice. 
  • Drug-Resistant Epimutants Exhibit Organ-Specific Stability and Induction during Murine Infections Caused by the Human Fungal Pathogen Mucor circinelloides. 
  • Drug-eluting stents in acute myocardial infarction: is science catching up with practice? 
  • Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 
  • Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. 
  • Economic impact of drug-eluting stents on hospital systems: a disease-state model. 
  • Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. 
  • Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. 
  • Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. 
  • Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. 
  • Effects of Immunosuppressive Medications on Mitochondrial Function. 
  • Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 
  • Efficacy and safety of mammalian target of rapamycin inhibitors following intestinal and multivisceral transplantation. 
  • Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 
  • Endolysosomal membrane trafficking complexes drive nutrient-dependent TORC1 signaling to control cell growth in Saccharomyces cerevisiae. 
  • Everolimus in colorectal cancer. 
  • Everolimus tablets for patients with subependymal giant cell astrocytoma. 
  • Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. 
  • Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. 
  • FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity. 
  • Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial. 
  • Functional Characteristics and Phenotypic Plasticity of CD57+PD1- CD4 T Cells and Their Relationship with Transplant Immunosuppression. 
  • Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. 
  • Graft-versus-host disease prevention by rapamycin: cellular mechanisms. 
  • Gut stem cell aging is driven by mTORC1 via a p38 MAPK-p53 pathway. 
  • Hmo1p, a high mobility group 1/2 homolog, genetically and physically interacts with the yeast FKBP12 prolyl isomerase. 
  • Human protein phosphatase PP6 regulatory subunits provide Sit4-dependent and rapamycin-sensitive sap function in Saccharomyces cerevisiae. 
  • Human renal allograft rejection despite the absence of allogeneic passenger leukocytes. 
  • IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. 
  • Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. 
  • Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. 
  • Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. 
  • Immunoregulation and tolerance. 
  • Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus. 
  • In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
  • In-stent pseudo-restenosis due to an organized thrombus six months after implantation of a sirolimus-eluting stent. 
  • Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire? 
  • Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency. 
  • Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. 
  • Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 
  • Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. 
  • Initial experience using rapamycin immunosuppression in pediatric intestinal transplant recipients. 
  • Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. 
  • Integration of multi-omics data reveals interplay between brassinosteroid and Target of Rapamycin Complex signaling in Arabidopsis. 
  • Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions. 
  • Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. 
  • Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up. 
  • Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy. 
  • Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. 
  • Laryngeal transplantation in the setting of cancer: a rat model. 
  • Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. 
  • Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. 
  • Longevity-related molecular pathways are subject to midlife "switch" in humans. 
  • Lymphangioleiomyomatosis. 
  • MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1. 
  • MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. 
  • Maf1 is an essential mediator of diverse signals that repress RNA polymerase III transcription. 
  • Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast. 
  • Mechanisms of action of rapamycin in gliomas. 
  • Modulation of Xenogeneic T-cell Proliferation by B7 and mTOR Blockade of T Cells and Porcine Endothelial Cells. 
  • Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. 
  • Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. 
  • Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. 
  • NCCN Task Force Report: mTOR inhibition in solid tumors. 
  • Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. 
  • Natural product ligands of FKBP12: Immunosuppressive antifungal agents FK506, rapamycin, and beyond. 
  • Next-generation drug-eluting stents: a spirited step forward or more of the same. 
  • Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells. 
  • Nutrient signaling through TOR kinases controls gene expression and cellular differentiation in fungi. 
  • Obesity following kidney transplantation and steroid avoidance immunosuppression. 
  • On the Discovery of TOR As the Target of Rapamycin. 
  • Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial. 
  • Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. 
  • PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. 
  • Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. 
  • Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. 
  • Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. 
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 
  • Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. 
  • Portal venous donor-specific transfusion in conjunction with sirolimus prolongs renal allograft survival in nonhuman primates. 
  • Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients. 
  • Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. 
  • Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 
  • Preclinical Development of New Therapy for Glycogen Storage Diseases. 
  • Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. 
  • Prolyl isomerases in yeast. 
  • Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast. 
  • Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model. 
  • Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. 
  • Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. 
  • Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. 
  • Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. 
  • Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells. 
  • Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. 
  • Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. 
  • Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. 
  • Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. 
  • Rapamycin for chemoprevention of upper aerodigestive tract cancers. 
  • Rapamycin increases transforming growth factor-beta mRNA expression in immortalized rat proximal renal tubular cells. 
  • Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway. 
  • Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. 
  • Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats. 
  • Rapamycin-conditioned donor dendritic cells differentiate CD4CD25Foxp3 T cells in vitro with TGF-beta1 for islet transplantation. 
  • Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. 
  • Rapid and orthogonal logic gating with a gibberellin-induced dimerization system. 
  • Rapid regression of large cardiac rhabdomyomas in neonates after sirolimus therapy. 
  • Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. 
  • Renal endoplasmic reticulum stress is coupled to impaired autophagy in a mouse model of GSD Ia. 
  • Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. 
  • Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. 
  • Reply to M A Khattak et al. 
  • Restenosis rates following vertebral artery origin stenting: does stent type make a difference? 
  • Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. 
  • Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. 
  • Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. 
  • Sex, Region, and Outcomes After Revascularization. 
  • Signal-transduction cascades as targets for therapeutic intervention by natural products. 
  • Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. 
  • Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. 
  • Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. 
  • Sirolimus monotherapy following Campath-1H induction. 
  • Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. 
  • Size matters (but so does time), and it's OK to be different. 
  • Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. 
  • Stem-cell transplantation for sickle cell disease. 
  • Strategies for minimizing immunosuppression in kidney transplantation. 
  • Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. 
  • Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 
  • Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. 
  • Symptomatic pulmonary allograft Kaposi's sarcoma in two lung transplant recipients. 
  • System for integrated adherence monitoring: real-time non-adherence risk assessment in pediatric kidney transplantation. 
  • T cells and macrophages responding to oxidative damage cooperate in pathogenesis of a mouse model of age-related macular degeneration. 
  • TOR kinase homologs function in a signal transduction pathway that is conserved from yeast to mammals. 
  • TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. 
  • TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. 
  • Tacrolimus and sirolimus: when bad things happen to good drugs. 
  • Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. 
  • Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. 
  • Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. 
  • The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. 
  • The Cryptococcus neoformans Flc1 Homologue Controls Calcium Homeostasis and Confers Fungal Pathogenicity in the Infected Hosts. 
  • The TOR kinases link nutrient sensing to cell growth. 
  • The TOR signal transduction cascade controls cellular differentiation in response to nutrients. 
  • The TOR signaling cascade regulates gene expression in response to nutrients. 
  • The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study. 
  • The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. 
  • The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. 
  • The enigma of drug-eluting stents: hope, hype, humility, and advancing patient care. 
  • The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. 
  • The process of bringing new drug-eluting stents to market will they see the light of day? 
  • The protein kinase Tor1 regulates adhesin gene expression in Candida albicans. 
  • The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. 
  • The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. 
  • The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. 
  • The tor pathway regulates gene expression by linking nutrient sensing to histone acetylation. 
  • Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients. 
  • Tor and cyclic AMP-protein kinase A: two parallel pathways regulating expression of genes required for cell growth. 
  • Transposon mobilization in the human fungal pathogen Cryptococcus is mutagenic during infection and promotes drug resistance in vitro. 
  • Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. 
  • Treatment of Eosinophilic Fasciitis With Sirolimus. 
  • Treatment options in renal cell carcinoma: past, present and future. 
  • Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 
  • Uncontrolled transposition following RNAi loss causes hypermutation and antifungal drug resistance in clinical isolates of Cryptococcus neoformans. 
  • Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. 
  • Urolithin A attenuates severity of chronic pancreatitis associated with continued alcohol intake by inhibiting PI3K/AKT/mTOR signaling. 
  • Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. 
  • mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. 
  • nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. 
• 

  Keywords of People

  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Taylor, Gregory Alan, Professor in Medicine, Integrative Immunobiology
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society